Hormone Receptor-positive Breast Cancer Clinical Trials

18 studies are recruiting for hormone receptor-positive breast cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Study of Screening Brain MRIs in Stage IV Breast Cancer

   The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Morton Plant Mease- Baycare, Clearwater, Florida

   Locations

   2 in total

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT05115474 on ClinicalTrials.gov

2. BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

   This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Iowa Hospitals and Clinics, Iowa City, Iowa

   Locations

   14 in total

   Run by

   BeOne Medicines

   See if you can join NCT06756932 on ClinicalTrials.gov

3. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

   This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado

   Locations

   62 in total

   Run by

   BeOne Medicines

   See if you can join NCT06120283 on ClinicalTrials.gov

4. PRE-ISPY Phase I/II Oncology Platform Program

   PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama

   Locations

   10 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT05868226 on ClinicalTrials.gov

5. PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

   The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer. This study is designed for participants with cancer that has previously stopped responding to medi…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Run by

   Kristina A. Fanucci

   See if you can join NCT07222215 on ClinicalTrials.gov

6. ETHAN - ET for Male BC

   This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemacicl…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Georgetown University Medical Center, Washington D.C., District of Columbia

   Locations

   9 in total

   Run by

   Jose Pablo Leone

   See if you can join NCT05501704 on ClinicalTrials.gov

7. Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

   The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal g…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Baptist Health Herbert Wertheim Cancer Institute, Miami, Florida

   Locations

   3 in total

   Run by

   Reshma L. Mahtani, D.O.

   See if you can join NCT06263543 on ClinicalTrials.gov

8. Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

   This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   21 in total

   Run by

   Oana Danciu

   See if you can join NCT05467891 on ClinicalTrials.gov

9. Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

   The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   14 in total

   Run by

   Ellipses Pharma

   See if you can join NCT05573126 on ClinicalTrials.gov

10. Study of XB010 in Subjects With Solid Tumors

    This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California

    Locations

    20 in total

    Run by

    Exelixis

    See if you can join NCT06545331 on ClinicalTrials.gov

11. ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

    This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are n…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Laura Huppert, MD, BA

    See if you can join NCT06224673 on ClinicalTrials.gov

12. DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

    This study is being done to determine if there is a pattern associated with response to endocrine therapy alone and in combination with CDK4/6 inhibitor used for hormone receptor positive HER2 negative breast cancer.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Run by

    Mayo Clinic

    See if you can join NCT06388122 on ClinicalTrials.gov

13. A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

    The purpose of this study is to test different doses of abemaciclib to find the best dose in participants while receiving hormone therapy and radiation therapy.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (All protocol activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06678269 on ClinicalTrials.gov

14. VS-6766+Abema+Fulv in Met HR+/HER- BC

    This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Adrienne G. Waks

    See if you can join NCT05608252 on ClinicalTrials.gov

15. Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

    This is a phase 2, open-label, singled-arm clinical trial determining efficacy of combination therapy with anastrozole, fulvestrant and abemaciclib in subjects with breast cancer. These are subjects who are newly diagnosed advanced or metastatic hormone receptor positive breast cancer or subjects w…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT05524584 on ClinicalTrials.gov

16. A Study of Revaree Plus in People With Breast Cancer

    The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07042581 on ClinicalTrials.gov

17. Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

    This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolerability of tirzepati…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey

    Locations

    7 in total

    Run by

    Rutgers, The State University of New Jersey

    See if you can join NCT06518837 on ClinicalTrials.gov

18. Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

    The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving c…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Harris Health System - Smith Clinic, Houston, Texas

    Locations

    2 in total

    Run by

    Baylor Breast Care Center

    See if you can join NCT05020860 on ClinicalTrials.gov